Persistent infection with oncogenic types of human papillomavirus (HPV) is commonly detected in the pre-cancerous lesions and invasive cancers of female lower genital organs. Currently, over 200 HPV genotypes have been identified. With the knowledge of HPV in female genital tracts infection and carcinogenesis advanced, HPV testing has recently been recommended as one of the primary screening methods for cervical cancer prevention.
However, understanding HPV at a systematic level is lacking and disconnected. For example, the development and evaluation of new HPV vaccines face challenges related to efficacy, safety, and scalability. Viral persistence mechanisms and immune interaction among HPV subtypes require in-depth molecular and cellular studies. Addressing the long-term effectiveness of vaccination is another challenge. How bridge the gap between research and health policy for translating scientific findings into actionable guidelines is also difficult.
This Research Topic aims to offer a forum for discussing new discoveries on HPV carcinogenesis, viral interaction, immune interaction, immune balance and escape among HPV viral subtypes and with other viruses, immune intervention for HPV infections; as well as updated information on cervical cancer screening/prevention guideline, and clinical management. On the global scale, it is of particular interest under-addressed and different levels of HPV research that face key challenges including basic science research, translational research, epidemiological research, and implementation sciences.
We welcome manuscripts focused on the most recent advances in HPV or HPV-related women's lower genital malignancies, in regard to cancer prevention, diagnosis, and treatment. The subtopics include, but are not limited to the following:
1. HPV carcinogenesis, viral interaction, viral persistence, populational features of HPV infection (Review, Original Research, and Clinical Research).
2. Cervical and anal cancer screening/prevention by HPV testing, HPV self-testing, and HPV testing performance (Original Research).
3. Discoveries of HPV carcinogenesis, HPV genotyping, immune balance and escape among HPV viral subtypes and with other viruses, immune intervention for HPV infection in women (Original Research).
4. Advances and current status of HPV vaccine and performance of HPV vaccine worldwide (Review and Original Research).
5. Advances and updates in clinical management and guidelines in HPV-positive women (Review and Original Research).
6. Socioeconomic, cultural, and demographic features linked to HPV infections, female lower genital cancer development and prevention (Original Research).
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Persistent infection with oncogenic types of human papillomavirus (HPV) is commonly detected in the pre-cancerous lesions and invasive cancers of female lower genital organs. Currently, over 200 HPV genotypes have been identified. With the knowledge of HPV in female genital tracts infection and carcinogenesis advanced, HPV testing has recently been recommended as one of the primary screening methods for cervical cancer prevention.
However, understanding HPV at a systematic level is lacking and disconnected. For example, the development and evaluation of new HPV vaccines face challenges related to efficacy, safety, and scalability. Viral persistence mechanisms and immune interaction among HPV subtypes require in-depth molecular and cellular studies. Addressing the long-term effectiveness of vaccination is another challenge. How bridge the gap between research and health policy for translating scientific findings into actionable guidelines is also difficult.
This Research Topic aims to offer a forum for discussing new discoveries on HPV carcinogenesis, viral interaction, immune interaction, immune balance and escape among HPV viral subtypes and with other viruses, immune intervention for HPV infections; as well as updated information on cervical cancer screening/prevention guideline, and clinical management. On the global scale, it is of particular interest under-addressed and different levels of HPV research that face key challenges including basic science research, translational research, epidemiological research, and implementation sciences.
We welcome manuscripts focused on the most recent advances in HPV or HPV-related women's lower genital malignancies, in regard to cancer prevention, diagnosis, and treatment. The subtopics include, but are not limited to the following:
1. HPV carcinogenesis, viral interaction, viral persistence, populational features of HPV infection (Review, Original Research, and Clinical Research).
2. Cervical and anal cancer screening/prevention by HPV testing, HPV self-testing, and HPV testing performance (Original Research).
3. Discoveries of HPV carcinogenesis, HPV genotyping, immune balance and escape among HPV viral subtypes and with other viruses, immune intervention for HPV infection in women (Original Research).
4. Advances and current status of HPV vaccine and performance of HPV vaccine worldwide (Review and Original Research).
5. Advances and updates in clinical management and guidelines in HPV-positive women (Review and Original Research).
6. Socioeconomic, cultural, and demographic features linked to HPV infections, female lower genital cancer development and prevention (Original Research).
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
